Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Wilson Sonsini says it advised Iambic Therapeutics on its $150 million IPO
Wilson Sonsini said it advised Iambic Therapeutics on a $150 million initial public offering. The firm described Iambic as a clinical-stage life sciences and technology company using an AI-driven platform, and said its shares began Nasdaq Global Select Market trading on October 15, 2026, under IAM.
Key points
- Wilson Sonsini reported 9,375,000 shares offered at $16 each.Wilson Sonsini
- The firm said underwriters have a 30-day option to purchase up to 1,406,250 additional shares.Wilson Sonsini
- Wilson Sonsini named J.P. Morgan, Jefferies, BofA Securities and Citigroup as joint book-running managers.Wilson Sonsini
- The firm said its team included corporate, patents and innovations, and benefits and compensation lawyers.Wilson Sonsini